Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Intellectual property legal development expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:IntellectualPropertyLegalDevelopmentExpenses.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Gross profit | 207,229 | 101,030 | 26,249 | — | 334,508 |
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — intellectual property legal development expenses of $2M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses increased by 1.2% year-over-year, from $1.98M to $2M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses has grown at a 20.2% compound annual growth rate (CAGR), from $4.25M to $7.39M.
- What does affordable medicines — intellectual property legal development expenses mean?
- Tracks the legal costs associated with securing, defending, and maintaining intellectual property rights for products within the Affordable Medicines segment. These expenses are critical for protecting the company's competitive advantage and market exclusivity.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude